# A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

> **NCT06277245** · PHASE3 · COMPLETED · sponsor: **Lynk Pharmaceuticals Co., Ltd** · enrollment: 356 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LNK01001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06277245
- **Lead sponsor:** Lynk Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-06
- **Primary completion:** 2025-04-18
- **Final completion:** 2026-01-12
- **Target enrollment:** 356 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06277245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06277245, "A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06277245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*